A Clinical Trial of CAP-003 Gene Therapy in Adult Patients With GBA1 Associated Parkinson's Disease

Summary

The goal of this clinical trial is to learn about the safety of CAP-003 gene therapy in adults with GBA1 associated Parkinson's Disease. It will also provide information about whether CAP-003 demonstrates efficacy in these adults. Participants will have a single intravenous infusion of CAP-003 and visit the clinic regularly for 2 years for checkups and tests.

Timeline

Start

2025-08-18

Primary completion

2026-06-17

Completion

2026-06-17

Outcome

Outcome not reported

Stopped: “Per protocol stopping rule was met for a separate trial for a different disease state and different experimental therapy that utilized a similar technology.”

Drugs

Indications